人尿激肽原酶治疗急性缺血性卒中功能结局
基于中国多中心前瞻性登记研究CASTOR的回顾性分析,按入院NIHSS评分分为轻度和中度组,倾向性评分匹配后比较HUK与非HUK治疗患者3个月mRS≤1比例。结果显示HUK组在轻度和中度组均显著高于对照组,提示HUK可能改善急性缺血性卒中预后,但需随机对照试验证实。
要点
- HUK治疗与轻度急性缺血性卒中3个月良好功能结局比例显著提高相关。
- HUK治疗与中度急性缺血性卒中3个月良好功能结局比例显著提高相关。
- 结论需进一步严格设计的随机对照试验证实。
核心结论
- HUK治疗对轻度和中度急性缺血性卒中患者的预后改善具有潜在疗效。
研究设计与样本
- 回顾性提取自CASTOR研究,该研究为2015至2019年中国前瞻性多中心研究。
- 按入院NIHSS评分分为轻度组(0-5分)和中度组(6-25分)。
- 采用倾向性评分匹配按HUK与非HUK 1:1匹配后分析。
主要发现
- 轻度组平均年龄63.5±11.7岁,女性占31.91%。
- 中度组平均年龄64.7±10.9岁,女性占36.78%。
- 3个月随访时,轻度组HUK治疗患者达到主要结局的比例为76.89%(1647/2142),对照组为74.13%(1588/2142),P=0.0013。
- 中度组HUK治疗患者达到主要结局的比例为43.10%(484/1123),对照组为38.02%(427/1123),P=0.03。
关键数值与推荐
- 主要结局为发病后3个月改良Rankin量表评分≤1的患者比例。
临床怎么用
- 对于轻度和中度急性缺血性卒中患者,HUK治疗可能有助于改善3个月功能结局。
- 临床应用需结合患者具体情况,并等待随机对照试验进一步验证。
局限性
- 本研究为回顾性分析,可能存在残余混杂。
- 需额外严格设计的随机对照试验证实 findings。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The neurorestorative potential of HUK (human urinary kallidinogenase) has drawn considerable clinical attention. Our study aimed to explore the therapeutic efficacy of HUK in patients with acute ischemic stroke. METHODS: Our data were retrospectively extracted from CASTOR (Chinese Acute Ischemic Stroke Treatment Outcome Registry), a prospective, multicenter study from 2015 to 2019 in China. The data was separated into 2 categories, the mild group (0-5 points) and the moderate group (6-25 points), according to the National Institutes of Health Stroke Scale score measured at admission and analyzed by propensity score matching with HUK or non-HUK ratio of 1:1. The percentage of patients with modified Rankin Scale score ≤1 at 3 months after onset was the primary outcome. RESULTS: Ten thousand two patients were recruited, after the criteria were filtered, 9005 patients were investigated. Following propensity score matching, a total of 6530 patients were ultimately enrolled in the analysis, consisting of 4284 patients in the mild group and 2246 patients in the moderate group. In the mild group, the mean age was 63.5±11.7 years, and females accounted for 31.91%. In the moderate group, the mean age was 64.7±10.9 years, and females occupied a proportion of 36.78%. At the 3-month follow-up, a significantly higher proportion of HUK-treated patients achieved the primary outcome compared with controls in both mild (76.89% [1647/2142] versus 74.13% [1588/2142]; P=0.0013) and moderate (43.10% [484/1123] versus 38.02% [427/1123]; P=0.03) groups. CONCLUSIONS: HUK therapy has potential efficacy in improving the prognosis of patients with both mild and moderate severity of acute ischemic stroke. Nevertheless, additional rigorously designed randomized controlled trials are essential to substantiate these findings. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02470624.
引用
- Huang D, Lu Y, Sun W, et al. Functional Outcomes of Human Urinary Kallindinogenases in Treatment of Acute Ischemic Stroke. Stroke. 2025. PMID: 41017461. doi:10.1161/STROKEAHA.124.050188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。